SecBot SecBot
8-K ·Filed Jul 24, 2026

MNKD

MANNKIND CORP
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-316041
8-K context-dependent: Items 3.02, 8.01
Actionable Insight ◆ Mixed

The FDA approval of Furoscix ReadyFlow is a major catalyst that could drive near-term upside, but the dilutive $50M raise at a ~$3.89 price (likely at a discount to market) to fund the associated CVR payment introduces overhang. Traders should watch for the resale registration statement filing (due ~Aug 23) and initial sales data for Furoscix ReadyFlow to gauge commercial traction. The combination of a new product launch and a clean balance sheet post-CVR payment could support the stock, but the dilution and the fact that the raise was needed to meet a known obligation suggest limited near-term upside.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.95
T+0 close · Jul 24, 2026 · via day close
Latest settled
−21.77%
T+60 · $3.09
Vs SPY
−25.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $3.95entry
  2. T+1 · 4mo ago −1.01%α −1.25% · $3.91
  3. T+5 · 4mo ago −1.01%α −2.09% · $3.91
  4. T+20 · 3mo ago +3.04%α −0.26% · $4.07
  5. T+60 · 28d ago −21.77%α −25.48% · $3.09
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind raised $50M via a private placement of 10.4M shares at $3.89/share and 2.4M pre-funded warrants at $3.88/share, with proceeds earmarked for general corporate purposes including a $45M CVR payment triggered by the FDA approval of Furoscix ReadyFlow. The FDA approval of Furoscix ReadyFlow for edema in heart failure or chronic kidney disease is a significant regulatory milestone that validates the company's pipeline and triggers the CVR liability. The combination of dilutive financing to meet a known obligation and a major product approval creates a mixed picture: the approval is a clear positive catalyst, but the immediate need to raise capital at a discount to fund the associated CVR payment tempers the bullish sentiment and signals potential cash constraints.

Key Financial Metrics

Offering Size
$50.0M

Key Facts

  • MannKind raised $50.0 million in a private placement of 10,440,838 shares at $3.89/share and 2,412,632 pre-funded warrants at $3.88/share.
  • The FDA approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema in adults with heart failure or chronic kidney disease.
  • Net proceeds will fund general corporate purposes, including a $45.0 million contingent value rights (CVR) payment triggered by the FDA approval.
  • The private placement was led by Frazier Life Sciences, a longstanding biotech investment firm.
  • The pre-funded warrants have a $0.01 exercise price, do not expire, and include a 4.99% beneficial ownership limitation (waivable to 19.99%).
  • MannKind agreed to file a resale registration statement within 30 days of closing, with liquidated damages of 1.0% per 30-day period for delays (capped at 5.0% of purchase price).

Financial Impact

$50.0 million gross proceeds from private placement; $45.0 million CVR payment obligation triggered by FDA approval

dilutioncashdebt

Risk Factors

  • Dilution of ~12.9% from the 12.9M new shares (common + warrant shares) against a ~100M share base (estimated from $1.2B market cap at ~$12/share) could pressure the stock.
  • The $45M CVR payment consumes most of the gross proceeds, leaving limited cash for other corporate purposes.
  • The resale registration statement may face SEC delays, triggering liquidated damages and overhang.
  • Furoscix ReadyFlow commercial launch may underperform expectations, limiting the approval's positive impact.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-316041
Document: d63182dex41.htm0001193125-26-316041
Document: d63182d8k.htm0001193125-26-316041
Document: d63182dex991.htm0001193125-26-316041
Document: 0001193125-26-316041-index-headers.html0001193125-26-316041
Document: 0001193125-26-316041-index.html0001193125-26-316041
Document: 0001193125-26-316041.txt0001193125-26-316041

Track record

17 reports on MNKD

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Viewing Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026